Psychedelic Research and Access in
South Korea
Blossom currently tracks 6 psychedelic clinical trials connected to South Korea, including 1 active study. The country page also links to 2 stakeholders, giving the page ecosystem context beyond registered studies.
Data updated
Key Insights
A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inSouth Korea.
- 1
Blossom tracks 6 psychedelic clinical trials connected to South Korea, including 1 active study.
- 2
Visible trial compounds include Esketamine.
- 3
Visible trial topics include Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
- 4
The country page links to 2 stakeholders in Blossom's ecosystem data.
- 5
The country access guide currently classifies access as "Medical Only (Private)"; details vary by compound and care setting.
Research and Access Snapshot
Blossom currently tracks 6 psychedelic clinical trials connected to South Korea, including 1 active study.
- Active trials
- 1
- Total trials
- 6
- Stakeholders
- 1
- Events
- 0
Currently active studies
Linked to this country
Linked organisations
No linked events
Top Compounds
- Esketamine(6)
Top Study Topics
- Treatment-Resistant Depression (TRD)(4)
- Major Depressive Disorder (MDD)(2)
Active Trial Preview
View all trials →Medical Access
South Korea maintains a restrictive legal regime for classical psychedelics: most serotonergic/hallucinogenic compounds (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca/DMT-containing plants, mescaline, 2C-X) are controlled under the national Narcotics Control Act and have no authorized medical use outside approved research. Esketamine is an exception - it received domestic marketing authorization and is available through regulated medical settings, while racemic/other ketamine formulations remain legal for approved medical uses (anesthesia...
Research Landscape
What the 6 registered trials connected to South Korea look like when you line them up. Counts come from Blossom’s trial records as of July 2026.
What's live right now, and what stopped?
SourcedRegistry status of all 6 South Korea trials Blossom tracks. Orange marks trials recruiting or opening.
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.
Regulatory Status
The linked medical access and reimbursement guide summarises South Korea as "Medical Only (Private)". South Korea maintains a restrictive legal regime for classical psychedelics: most serotonergic/hallucinogenic compounds (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca/DMT-containing plants, mescaline, 2C-X) are controlled under the national Narcotics Control Act and have no authorized medical use outside approved research. Esketamine is an exception - it received domestic marketing authorization and is available through regulated medical settings, while racemic/other ketamine formulations remain legal for approved medical uses (anesthesia, analgesia) and are used off-label in private psychiatric practice for depression but generally without routine public.
Country Details
- Region
- Asia
- Last updated
- 15 Jul 2026
Country Report
Medical Only (Private)Medical Access
South Korea maintains a restrictive legal regime for classical psychedelics: most serotonergic/hallucinogenic compounds (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca/DMT-containing plants, mescaline, 2C-X) are controlled under the national Narcotics Control Act and have no authorized...
Open access guide →Pro Scorecard
Country Scorecard
Compare evidence, access, payment, delivery, local ecosystem, and review confidence for South Korea.
Open scorecard →Psychedelic Stakeholders in South Korea
Organisations, sponsors, clinics, and research groups connected to psychedelic science in South Korea.
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in South Korea.